CY1114866T1 - Μεθοδος για την παραγωγη αμινοκροτονυλικων ενωσεων - Google Patents

Μεθοδος για την παραγωγη αμινοκροτονυλικων ενωσεων

Info

Publication number: CY1114866T1
Authority: CY; Cyprus
Prior art keywords: amino; producing; compounds; aminocrotonyl; buten
Prior art date: 2003-10-17

Application number

CY20131101112T

Other languages

Greek (el)

English (en)

Inventor

Werner Rall

Rainer Soyka

Christian Kulinna

Juergen Schnaubelt

Peter Sieger

Original Assignee

Boehringer Ingelheim International Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-17

Filing date

2013-12-09

Publication date

2016-12-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34428508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114866(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-12-09 Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh

2016-12-14 Publication of CY1114866T1 publication Critical patent/CY1114866T1/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CY20131101112T 2003-10-17 2013-12-09 Μεθοδος για την παραγωγη αμινοκροτονυλικων ενωσεων CY1114866T1 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10349113A DE10349113A1 (de)	2003-10-17	2003-10-17	Verfahren zur Herstellung von Aminocrotonylverbindungen
EP04765927.1A EP1678165B1 (fr)	2003-10-17	2004-10-12	Procede de production de composes aminocrotonyliques

Publications (1)

Publication Number	Publication Date
CY1114866T1 true CY1114866T1 (el)	2016-12-14

Family

ID=34428508

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY20131101112T CY1114866T1 (el)	2003-10-17	2013-12-09	Μεθοδος για την παραγωγη αμινοκροτονυλικων ενωσεων
CY20161100212T CY1117279T1 (el)	2003-10-17	2016-03-11	Διμηλεϊνκο αλας μιας αμινοκροτονυλικης ενωσης και μεθοδος για την παραγωγη τους

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CY20161100212T CY1117279T1 (el)	2003-10-17	2016-03-11	Διμηλεϊνκο αλας μιας αμινοκροτονυλικης ενωσης και μεθοδος για την παραγωγη τους

Country Status (34)

Country	Link
US (2)	US20050085495A1 (fr)
EP (2)	EP1678165B1 (fr)
JP (2)	JP4594317B2 (fr)
KR (2)	KR101282812B1 (fr)
CN (2)	CN101402631A (fr)
AR (1)	AR046118A1 (fr)
AU (2)	AU2004281938B2 (fr)
BR (2)	BR122013033343B8 (fr)
CA (2)	CA2541928C (fr)
CY (2)	CY1114866T1 (fr)
DE (1)	DE10349113A1 (fr)
DK (2)	DK2508521T4 (fr)
EA (1)	EA016624B1 (fr)
EC (1)	ECSP066509A (fr)
ES (2)	ES2440466T3 (fr)
HR (2)	HRP20160246T4 (fr)
HU (1)	HUE028254T2 (fr)
IL (2)	IL174951A (fr)
ME (1)	ME00341B (fr)
MX (2)	MXPA06004076A (fr)
MY (2)	MY155425A (fr)
NO (2)	NO333971B1 (fr)
NZ (2)	NZ583049A (fr)
PE (2)	PE20050965A1 (fr)
PL (2)	PL1678165T3 (fr)
PT (2)	PT2508521E (fr)
RS (3)	RS53398B (fr)
SG (1)	SG139743A1 (fr)
SI (2)	SI1678165T1 (fr)
TW (2)	TWI373470B (fr)
UA (2)	UA91401C2 (fr)
UY (2)	UY28559A1 (fr)
WO (1)	WO2005037824A2 (fr)
ZA (1)	ZA200602234B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000078735A1 (fr)	1999-06-21	2000-12-28	Boehringer Ingelheim Pharma Kg	Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les preparer
US7019012B2 (en) *	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
KR100832593B1 (ko) *	2005-11-08	2008-05-27	한미약품 주식회사	신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법
SI1948180T1 (sl) *	2005-11-11	2013-06-28	Boehringer Ingelheim International Gmbh	Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
JP5688877B2 (ja) *	2005-11-11	2015-03-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	癌疾患の治療用キナゾリン誘導体
DK1981863T3 (da) *	2006-01-26	2013-01-02	Boehringer Ingelheim Int	Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater
SI2068880T1 (sl) *	2006-09-18	2012-08-31	Boehringer Ingelheim Int	Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
PE20100252A1 (es) *	2008-06-06	2010-04-12	Boehringer Ingelheim Int	Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
WO2010081817A1 (fr)	2009-01-14	2010-07-22	Boehringer Ingelheim International Gmbh	Méthode de traitement d'un cancer colorectal
MX2011009034A (es)	2009-03-11	2011-09-22	Auckland Uniservices Ltd	Formas de profarmaco de inhibidores de cinasa y su uso en la terapia.
EP2429520A1 (fr)	2009-05-14	2012-03-21	Boehringer Ingelheim International GmbH	Nouvelle polytherapie destinee a traiter les maladies oncologiques et fibrotiques
AU2010266725A1 (en)	2009-07-02	2012-02-23	Newgen Therapeutics, Inc.	Phosphorus containing quinazoline compounds and methods of use
JP5963672B2 (ja)	2009-07-06	2016-08-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法
EP2509592A1 (fr)	2009-12-07	2012-10-17	Boehringer Ingelheim International GmbH	Bibw 2992 pour utilisation dans le traitement du cancer du sein triple négatif
US20120107304A1 (en) *	2010-04-27	2012-05-03	Boehringer Ingelheim International Gmbh	Combination therapy in treatment of oncological and fibrotic diseases
DK2608792T3 (en)	2010-08-26	2018-01-15	Boehringer Ingelheim Int	PROCEDURES FOR SUBMITTING AN EGFR INHIBITOR.
US9012464B2 (en)	2010-11-25	2015-04-21	Ratiopharm Gmbh	Salts and polymorphic forms of Afatinib
KR20200003933A (ko)	2011-03-04	2020-01-10	뉴젠 세러퓨틱스 인코포레이티드	알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102731485B (zh) *	2011-04-02	2016-06-15	齐鲁制药有限公司	4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
WO2012155339A1 (fr) *	2011-05-17	2012-11-22	江苏康缘药业股份有限公司	Dérivés de la 4-phénylamino-6-buténamide-7-alkyloxy quinazoline, leur procédé de préparation et leur utilisation
US8828391B2 (en)	2011-05-17	2014-09-09	Boehringer Ingelheim International Gmbh	Method for EGFR directed combination treatment of non-small cell lung cancer
CN102838590B (zh) *	2011-06-21	2014-07-09	苏州迈泰生物技术有限公司	氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
US20170079444A1 (en) *	2011-09-22	2017-03-23	Future Foam, Inc.	Enhanced washable mattress topper
EP2753616A1 (fr)	2011-10-06	2014-07-16	Ratiopharm GmbH	Formes cristallines de di-maléate d'afatinib
CN103073539B (zh) *	2011-10-26	2016-05-11	齐鲁制药有限公司	4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
WO2014012859A1 (fr)	2012-07-19	2014-01-23	Boehringer Ingelheim International Gmbh	Sel d'acide fumarique de la 9-[4-(3-chloro-2-fluoro-phénylamino)-7-méthoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undécan-5-one, son utilisation en tant que médicament et sa préparation
WO2014118197A1 (fr)	2013-02-01	2014-08-07	Boehringer Ingelheim International Gmbh	Dérivés de quinazoline radiomarqués
CN103254156B (zh) *	2013-05-10	2015-08-26	苏州明锐医药科技有限公司	阿法替尼中间体的制备方法
WO2014180271A1 (fr) *	2013-05-10	2014-11-13	苏州明锐医药科技有限公司	Procédé de préparation de l'afatinib et intermédiaire associé
CN103242303B (zh) *	2013-05-16	2015-03-25	苏州明锐医药科技有限公司	阿法替尼的制备方法
CN103288808B (zh) *	2013-05-16	2015-11-11	苏州明锐医药科技有限公司	一种阿法替尼的制备方法
WO2015007206A1 (fr) *	2013-07-16	2015-01-22	杭州普晒医药科技有限公司	Sels d'addition d'acide de l'afatinib et leurs formes cristallines, procédé de préparation et composition pharmaceutique correspondants
CN104513229A (zh) *	2013-09-28	2015-04-15	正大天晴药业集团股份有限公司	喹唑啉衍生物及其制备方法
CN104710413B (zh) *	2013-12-16	2019-05-03	江苏豪森药业集团有限公司	二马来酸阿法替尼的制备方法
CN104744445A (zh) *	2013-12-30	2015-07-01	广东东阳光药业有限公司	一种酪氨酸激酶抑制剂的晶型
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EA031059B1 (ru) *	2014-01-02	2018-11-30	Тева Фармасьютикалз Интернэшнл Гмбх	Кристаллическая форма альфа дималеата афатиниба
CN104803992A (zh) *	2014-01-25	2015-07-29	广东东阳光药业有限公司	阿法替尼盐的晶型
WO2016001844A1 (fr) *	2014-06-30	2016-01-07	Sun Pharmaceutical Industries Limited	Forme amorphe de dimaléate d'afatinib
CN105315263B (zh) *	2014-07-30	2018-11-27	正大天晴药业集团股份有限公司	阿法替尼中间体的合成方法
WO2016027243A1 (fr) *	2014-08-21	2016-02-25	Dr. Reddy’S Laboratories Limited	Nouvelles formes solides de dimaléate d'afatinib
WO2016051380A1 (fr) *	2014-10-01	2016-04-07	Sun Pharmaceutical Industries Limited	Forme cristalline de dimaléate d'afatinib
CN105534920B (zh) *	2014-10-29	2020-07-10	江苏豪森药业集团有限公司	一种药物组合物及其制备方法
CN104402872B (zh) *	2014-11-14	2016-08-24	广东东阳光药业有限公司	一种结晶除杂方法
CN104447713B (zh) *	2014-11-18	2019-03-29	江苏奥赛康药业股份有限公司	阿法替尼化合物的制备方法
EP3023421A1 (fr) *	2014-11-21	2016-05-25	Sandoz Ag	Formes cristallines de dimaléate d'afatinib
CN104529800B (zh) *	2014-12-08	2017-01-25	重庆威鹏药业有限公司	反式‑4‑二甲基氨基巴豆酸及盐的制备方法
CN105801567A (zh) *	2014-12-31	2016-07-27	徐州万邦金桥制药有限公司	一种双马来酸阿法替尼的纯化方法
CN105801568B (zh) *	2015-01-15	2019-07-30	杭州普晒医药科技有限公司	阿法替尼一马来酸盐晶型及其制备方法和药物组合物
JP6704422B2 (ja)	2015-03-20	2020-06-03	チアタイティエンチンファーマシューティカルグループカンパニーリミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd.	キナゾリン誘導体の塩およびその製造方法
JP2018511646A (ja) *	2015-04-17	2018-04-26	ヘテロラボズリミテッドＨｅｔｅｒｏＬａｂｓＬｔｄ	多形体及びキナゾリニル誘導体の調製プロセス
CN105859641B (zh) *	2015-05-05	2018-11-16	杭州华东医药集团新药研究院有限公司	喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
CN104892584B (zh) *	2015-05-27	2018-03-23	重庆泰濠制药有限公司	一种阿法替尼双马来酸盐无定型态及其制备方法、制剂
US10800763B2 (en)	2015-06-12	2020-10-13	Fresenius Kabi Oncology Ltd.	Polymorphic forms of Afatinib free base and Afatinib dimaleate
CN104926800A (zh) *	2015-06-26	2015-09-23	河北神威药业有限公司	一种阿法替尼二马来酸盐的结晶形式及其制备方法
CN105175331B (zh) *	2015-08-14	2019-04-26	江苏苏中药业集团股份有限公司	一种egfr类分子靶向抗肿瘤药物的制备方法
US10525059B2 (en)	2015-08-21	2020-01-07	Fresenius Kabi Oncology, Ltd.	Pharmaceutical compositions comprising Afatinib
WO2017093789A1 (fr) *	2015-12-03	2017-06-08	Mylan Laboratories Ltd.	Formes polymorphes de dimaléate d'afatinib
CN106831733B (zh) *	2015-12-07	2021-05-11	海南先声药业有限公司	阿法替尼顺式异构体的制备方法与应用
CN106866641A (zh) *	2015-12-11	2017-06-20	河北神威药业有限公司	一种阿法替尼的精制方法
CN106916147A (zh) *	2015-12-25	2017-07-04	中美华世通生物医药科技（武汉）有限公司	化合物及其制备方法和用途
CN108430990B (zh)	2015-12-25	2020-08-25	山东轩竹医药科技有限公司	喹唑啉衍生物的晶体及其制备方法
CN105669658B (zh) *	2016-04-05	2018-06-29	北京民康百草医药科技有限公司	一种阿法替尼的精制方法
CN107488194B (zh) *	2016-06-10	2021-07-30	山东新时代药业有限公司	一种阿法替尼中间体及其制备方法
CN107488172B (zh) *	2016-06-10	2020-06-12	山东新时代药业有限公司	一种阿法替尼的制备方法
CN107488153B (zh) *	2016-06-10	2020-06-23	山东新时代药业有限公司	一种阿法替尼中间体化合物
CN107488171B (zh) *	2016-06-10	2020-08-28	山东新时代药业有限公司	一种阿法替尼制备方法
CN106243092B (zh) *	2016-07-28	2019-02-15	南京臣功制药股份有限公司	一种高选择性制备马来酸阿法替尼的方法
MA46852A (fr)	2016-11-17	2019-09-25	Univ Texas	Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
TWI808958B (zh)	2017-01-25	2023-07-21	美商特普醫葯公司	涉及二芳基巨環化合物之組合療法
CN110461832A (zh)	2017-04-06	2019-11-15	庄信万丰股份有限公司	阿法替尼二马来酸盐的新形式
CN108358900A (zh) *	2018-03-30	2018-08-03	东北制药集团股份有限公司	一种阿法替尼及其马来酸盐的制备方法
KR20190141607A (ko)	2018-06-14	2019-12-24	주식회사 에이티파머	알로페론을 포함하는 췌장암 치료용 조성물 및 치료 보조제
KR102257913B1 (ko)	2018-07-17	2021-05-28	주식회사 에이티파머	알로페론을 포함하는 폐섬유증 치료용 조성물
CN109824657A (zh) *	2019-03-26	2019-05-31	石药集团中奇制药技术（石家庄）有限公司	一种二马来酸阿法替尼新晶型及其制备方法和应用
CN110590754A (zh) *	2019-09-21	2019-12-20	广东安诺药业股份有限公司	一种马来酸阿法替尼中间体的制备方法
CN110563710B (zh) *	2019-09-21	2020-05-19	广东安诺药业股份有限公司	一种马来酸阿法替尼的制备方法
CN113121512B (zh) *	2019-12-30	2022-11-04	江苏晶立信医药科技有限公司	一种喹唑啉基丁烯酰胺类化合物的制备方法
KR20210106157A (ko)	2020-02-20	2021-08-30	서울대학교산학협력단	알로페론을 포함하는 난소암 치료용 조성물 및 치료 보조제
KR20210106158A (ko)	2020-02-20	2021-08-30	서울대학교산학협력단	알로페론을 포함하는 항암 치료 보조제
CN114315808A (zh) *	2020-10-10	2022-04-12	西安新通药物研究有限公司	一种高收率马来酸阿法替尼的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8618846D0 (en)	1986-08-01	1986-09-10	Smithkline Beckman Corp	Chemical process
JPS6442472A (en)	1987-08-10	1989-02-14	Kanebo Ltd	Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
GB9005014D0 (en) *	1990-03-06	1990-05-02	Janssen Pharmaceutica Nv	N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
RU2043352C1 (ru) *	1991-07-01	1995-09-10	Пермский фармацевтический институт	2-пропил-3- (5-нитрофурфулиден)амино- 4(3н)-хиназолинон, проявляющий противостафилококковую и анальгетическую активность
GB9300059D0 (en)	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
GB9401182D0 (en)	1994-01-21	1994-03-16	Inst Of Cancer The Research	Antibodies to EGF receptor and their antitumour effect
DE69536015D1 (de)	1995-03-30	2009-12-10	Pfizer Prod Inc	Chinazolinone Derivate
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
DK0836605T3 (da)	1995-07-06	2002-05-13	Novartis Ag	Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
SK284073B6 (sk)	1996-04-12	2004-09-08	Warner-Lambert Company	Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
US6297258B1 (en) *	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
US6262088B1 (en)	1998-11-19	2001-07-17	Berlex Laboratories, Inc.	Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
AU3281600A (en) *	1999-02-27	2000-09-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
DE19911366A1 (de)	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911509A1 (de)	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2000078735A1 (fr)	1999-06-21	2000-12-28	Boehringer Ingelheim Pharma Kg	Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les preparer
US6627634B2 (en) *	2000-04-08	2003-09-30	Boehringer Ingelheim Pharma Kg	Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US20030158196A1 (en) *	2002-02-16	2003-08-21	Boehringer Ingelheim Pharma Gmbh Co. Kg	Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US7019012B2 (en) *	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (de)	2000-12-20	2002-07-04	Boehringer Ingelheim Pharma	Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10204462A1 (de) *	2002-02-05	2003-08-07	Boehringer Ingelheim Pharma	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
DE10221018A1 (de)	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20030225079A1 (en) *	2002-05-11	2003-12-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
PE20040945A1 (es) *	2003-02-05	2004-12-14	Warner Lambert Co	Preparacion de quinazolinas substituidas
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
US20060058311A1 (en) *	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
JP5688877B2 (ja)	2005-11-11	2015-03-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	癌疾患の治療用キナゾリン誘導体
SI1948180T1 (sl) *	2005-11-11	2013-06-28	Boehringer Ingelheim International Gmbh	Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
DK1981863T3 (da) *	2006-01-26	2013-01-02	Boehringer Ingelheim Int	Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater
SI2068880T1 (sl) *	2006-09-18	2012-08-31	Boehringer Ingelheim Int	Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
PE20100252A1 (es)	2008-06-06	2010-04-12	Boehringer Ingelheim Int	Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
WO2010081817A1 (fr)	2009-01-14	2010-07-22	Boehringer Ingelheim International Gmbh	Méthode de traitement d'un cancer colorectal
JP5963672B2 (ja) *	2009-07-06	2016-08-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法
EP2509592A1 (fr)	2009-12-07	2012-10-17	Boehringer Ingelheim International GmbH	Bibw 2992 pour utilisation dans le traitement du cancer du sein triple négatif
US9012464B2 (en)	2010-11-25	2015-04-21	Ratiopharm Gmbh	Salts and polymorphic forms of Afatinib
EP2753616A1 (fr)	2011-10-06	2014-07-16	Ratiopharm GmbH	Formes cristallines de di-maléate d'afatinib
WO2015007206A1 (fr)	2013-07-16	2015-01-22	杭州普晒医药科技有限公司	Sels d'addition d'acide de l'afatinib et leurs formes cristallines, procédé de préparation et composition pharmaceutique correspondants
WO2016027243A1 (fr)	2014-08-21	2016-02-25	Dr. Reddy’S Laboratories Limited	Nouvelles formes solides de dimaléate d'afatinib
CN104892584B (zh)	2015-05-27	2018-03-23	重庆泰濠制药有限公司	一种阿法替尼双马来酸盐无定型态及其制备方法、制剂
CN104926800A (zh)	2015-06-26	2015-09-23	河北神威药业有限公司	一种阿法替尼二马来酸盐的结晶形式及其制备方法

2003
- 2003-10-17 DE DE10349113A patent/DE10349113A1/de not_active Withdrawn
2004
- 2004-09-15 US US10/941,116 patent/US20050085495A1/en not_active Abandoned
- 2004-10-12 PT PT121556625T patent/PT2508521E/pt unknown
- 2004-10-12 UA UAA200810609A patent/UA91401C2/ru unknown
- 2004-10-12 KR KR1020127003787A patent/KR101282812B1/ko not_active Expired - Lifetime
- 2004-10-12 SG SG200800279-2A patent/SG139743A1/en unknown
- 2004-10-12 CA CA2541928A patent/CA2541928C/fr not_active Expired - Lifetime
- 2004-10-12 MX MXPA06004076A patent/MXPA06004076A/es active IP Right Grant
- 2004-10-12 BR BR122013033343A patent/BR122013033343B8/pt active IP Right Grant
- 2004-10-12 ME MEP-2008-508A patent/ME00341B/fr unknown
- 2004-10-12 PT PT47659271T patent/PT1678165E/pt unknown
- 2004-10-12 MX MX2011004537A patent/MX338920B/es unknown
- 2004-10-12 DK DK12155662.5T patent/DK2508521T4/da active
- 2004-10-12 CA CA2759063A patent/CA2759063C/fr not_active Expired - Lifetime
- 2004-10-12 CN CNA2008101664841A patent/CN101402631A/zh active Pending
- 2004-10-12 ES ES04765927.1T patent/ES2440466T3/es not_active Expired - Lifetime
- 2004-10-12 HU HUE12155662A patent/HUE028254T2/en unknown
- 2004-10-12 HR HRP20160246TT patent/HRP20160246T4/hr unknown
- 2004-10-12 SI SI200432099T patent/SI1678165T1/sl unknown
- 2004-10-12 UA UAA200605327A patent/UA91006C2/ru unknown
- 2004-10-12 NZ NZ583049A patent/NZ583049A/en not_active IP Right Cessation
- 2004-10-12 BR BRPI0415424A patent/BRPI0415424B8/pt active IP Right Grant
- 2004-10-12 NZ NZ547154A patent/NZ547154A/en not_active IP Right Cessation
- 2004-10-12 HR HRP20131214TT patent/HRP20131214T1/hr unknown
- 2004-10-12 DK DK04765927.1T patent/DK1678165T3/da active
- 2004-10-12 EP EP04765927.1A patent/EP1678165B1/fr not_active Expired - Lifetime
- 2004-10-12 ES ES12155662T patent/ES2563211T5/es not_active Expired - Lifetime
- 2004-10-12 SI SI200432301T patent/SI2508521T2/sl unknown
- 2004-10-12 RS RS20060260A patent/RS53398B/sr unknown
- 2004-10-12 AU AU2004281938A patent/AU2004281938B2/en not_active Expired
- 2004-10-12 JP JP2006534662A patent/JP4594317B2/ja not_active Expired - Lifetime
- 2004-10-12 RS YUP-2006/0260A patent/RS20060260A/sr unknown
- 2004-10-12 PL PL04765927T patent/PL1678165T3/pl unknown
- 2004-10-12 EA EA200600604A patent/EA016624B1/ru active Protection Beyond IP Right Term
- 2004-10-12 EP EP12155662.5A patent/EP2508521B2/fr not_active Expired - Lifetime
- 2004-10-12 PL PL12155662.5T patent/PL2508521T5/pl unknown
- 2004-10-12 CN CN2004800305555A patent/CN1867564B/zh not_active Expired - Lifetime
- 2004-10-12 RS RS20130524A patent/RS60563B1/sr unknown
- 2004-10-12 KR KR1020067009605A patent/KR101180752B1/ko not_active Expired - Lifetime
- 2004-10-12 WO PCT/EP2004/011378 patent/WO2005037824A2/fr not_active Ceased
- 2004-10-14 UY UY28559A patent/UY28559A1/es not_active IP Right Cessation
- 2004-10-14 MY MYPI2010002645A patent/MY155425A/en unknown
- 2004-10-14 MY MYPI20044237A patent/MY149921A/en unknown
- 2004-10-15 AR ARP040103754A patent/AR046118A1/es not_active Application Discontinuation
- 2004-10-15 PE PE2004001000A patent/PE20050965A1/es active IP Right Grant
- 2004-10-15 TW TW099147116A patent/TWI373470B/zh not_active IP Right Cessation
- 2004-10-15 PE PE2010000135A patent/PE20100267A1/es not_active Application Discontinuation
- 2004-10-15 TW TW093131395A patent/TWI348468B/zh not_active IP Right Cessation
2006
- 2006-03-16 ZA ZA200602234A patent/ZA200602234B/en unknown
- 2006-04-11 IL IL174951A patent/IL174951A/en active IP Right Grant
- 2006-04-17 EC EC2006006509A patent/ECSP066509A/es unknown
- 2006-05-15 NO NO20062181A patent/NO333971B1/no unknown
- 2006-07-14 US US11/457,622 patent/US8426586B2/en active Active
2010
- 2010-06-21 JP JP2010140697A patent/JP5264830B2/ja not_active Expired - Lifetime
2011
- 2011-03-16 AU AU2011201171A patent/AU2011201171B2/en active Active
- 2011-11-10 IL IL216249A patent/IL216249A/en active IP Right Grant
2013
- 2013-05-10 NO NO20130663A patent/NO335103B1/no unknown
- 2013-12-09 CY CY20131101112T patent/CY1114866T1/el unknown
2015
- 2015-02-04 UY UY0001035979A patent/UY35979A/es not_active IP Right Cessation
2016
- 2016-03-11 CY CY20161100212T patent/CY1117279T1/el unknown

Also Published As

Publication number	Publication date
EA200600604A1 (ru)	2006-10-27
UA91006C2 (ru)	2010-06-25
CA2759063C (fr)	2012-04-17
BR122013033343B1 (pt)	2020-10-13
MX338920B (es)	2016-05-06
HK1095817A1 (en)	2007-05-18
ZA200602234B (en)	2007-09-26
NO20062181L (no)	2006-05-15
JP5264830B2 (ja)	2013-08-14
US8426586B2 (en)	2013-04-23
ES2563211T5 (es)	2022-12-27
IL174951A0 (en)	2006-08-20
US20050085495A1 (en)	2005-04-21
DE10349113A1 (de)	2005-05-12
EP2508521B2 (fr)	2022-09-07
DK2508521T4 (da)	2022-10-03
CA2759063A1 (fr)	2005-04-28
BRPI0415424A (pt)	2006-12-05
TWI348468B (en)	2011-09-11
NZ583049A (en)	2011-08-26
SI2508521T2 (sl)	2022-11-30
KR101180752B1 (ko)	2012-09-10
KR20120037987A (ko)	2012-04-20
WO2005037824A2 (fr)	2005-04-28
JP2007510624A (ja)	2007-04-26
ES2563211T3 (es)	2016-03-11
CA2541928A1 (fr)	2005-04-28
UA91401C2 (en)	2010-07-26
NO335103B1 (no)	2014-09-15
TW200526644A (en)	2005-08-16
KR20060120121A (ko)	2006-11-24
HRP20160246T4 (hr)	2022-11-11
AU2011201171B2 (en)	2012-02-09
PL2508521T3 (pl)	2016-06-30
MEP50808A (en)	2011-02-10
IL216249A0 (en)	2011-12-29
AR046118A1 (es)	2005-11-23
RS20130524A2 (sr)	2014-06-30
AU2011201171A1 (en)	2011-04-07
CN101402631A (zh)	2009-04-08
CA2541928C (fr)	2012-12-11
IL174951A (en)	2012-03-29
JP2010202668A (ja)	2010-09-16
IL216249A (en)	2015-05-31
EA016624B1 (ru)	2012-06-29
EP2508521A2 (fr)	2012-10-10
PL1678165T3 (pl)	2014-03-31
DK2508521T3 (en)	2016-03-29
BRPI0415424B1 (pt)	2019-01-22
ECSP066509A (es)	2006-10-10
PL2508521T5 (pl)	2023-03-27
NO20130663L (no)	2006-05-15
DK1678165T3 (da)	2013-12-09
HRP20160246T1 (hr)	2016-04-08
WO2005037824A3 (fr)	2005-07-21
SG139743A1 (en)	2008-02-29
NO333971B1 (no)	2013-11-04
AU2004281938A1 (en)	2005-04-28
RS53398B (sr)	2014-10-31
PE20100267A1 (es)	2010-04-21
PE20050965A1 (es)	2005-12-19
RS60563B1 (sr)	2020-08-31
CN1867564A (zh)	2006-11-22
EP1678165A2 (fr)	2006-07-12
TW201118086A (en)	2011-06-01
MY149921A (en)	2013-10-31
HUE028254T2 (en)	2016-12-28
NZ547154A (en)	2010-02-26
ES2440466T3 (es)	2014-01-29
RS20060260A (sr)	2008-06-05
EP1678165B1 (fr)	2013-09-25
SI1678165T1 (sl)	2013-12-31
EP2508521A3 (fr)	2013-01-23
PT2508521E (pt)	2016-03-31
UY35979A (es)	2016-09-30
CN1867564B (zh)	2011-06-08
RS20130524A3 (en)	2015-08-31
ME00341B (fr)	2011-05-10
BRPI0415424B8 (pt)	2021-05-25
PT1678165E (pt)	2013-11-07
CY1117279T1 (el)	2017-04-26
HRP20131214T1 (hr)	2014-01-31
MXPA06004076A (es)	2006-06-27
BR122013033343B8 (pt)	2021-05-25
KR101282812B1 (ko)	2013-07-05
MY155425A (en)	2015-10-15
TWI373470B (en)	2012-10-01
SI2508521T1 (sl)	2016-03-31
UY28559A1 (es)	2005-05-31
US20070027170A1 (en)	2007-02-01
AU2004281938B2 (en)	2011-04-14
JP4594317B2 (ja)	2010-12-08
EP2508521B1 (fr)	2015-12-30

Publication	Publication Date	Title
CY1114866T1 (el)	2016-12-14	Μεθοδος για την παραγωγη αμινοκροτονυλικων ενωσεων
CY1106386T1 (el)	2011-10-12	Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
CY1106774T1 (el)	2012-05-23	Συνθεσεις φαρμακευτικων μεσων με βαση αλατα του τιοτροπιου και αλατα της σαλμετερολης
UY27755A1 (es)	2003-11-28	Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
EA200501849A1 (ru)	2006-06-30	Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
CY1115719T1 (el)	2017-01-25	Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
DK1660528T3 (da)	2010-01-04	Mutein af tåre-lipocalin
CY1110558T1 (el)	2015-04-29	Σπειροκυκλικα παραγωγα κυκλοεξανιου
DK1436381T3 (da)	2005-09-19	Dedifferentierede, programmerbare stamceller af monocytisk oprindelse og deres fremstilling og anvendelse
CY1112889T1 (el)	2016-04-13	Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
CY1109870T1 (el)	2014-09-10	ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΟΥ 1-ΧΛΩΡΟ-4-(β-D-ΓΛΥΚΟΠΥΡΑΝΟΖ-1-ΥΛ)-2-[4-((S)-ΤΕΤΡΑΫΔΡΟΦΟΥΡΑΝ-3-ΥΛΟΞΥ)-ΒΕΝΖΥΛ]-ΒΕΝΖΟΛΙΟΥ, ΜΕΘΟΔΟΣ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΑΥΤΟΥ ΚΑΙ Η ΧΡΗΣΗ ΑΥΤΟΥ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΦΑΡΜΑΚΩΝ
SE0401971D0 (sv)	2004-08-02	Piperidne derivatives
CY1106430T1 (el)	2011-10-12	Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
CY1109361T1 (el)	2014-07-02	Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1111022T1 (el)	2015-06-11	Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
NO20044547L (no)	2004-12-17	Nye farmasoytiske sammensetninger inneholdende flibanserin
EA200970192A1 (ru)	2009-08-28	Производные 5,6-бисарил-2-пиридин-карбоксамида, их получение и их применение в терапии в качестве антагонистов рецепторов уротензина ii
ATE410155T1 (de)	2008-10-15	Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
CY1107231T1 (el)	2012-11-21	Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
EA200601288A1 (ru)	2006-12-29	Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
EA200702004A1 (ru)	2008-02-28	Соль безилата 7-(2-(4-(3-трифторметилфенил)-1,2,3,6-тетрагидропирид-1-ил)этил)изохинолина, ее получение и применение в терапии
TH73090A (th)	2005-12-01	กรรมวิธีสำหรับการเตรียมสารประกอบอะมิโนโครโทนิล
DE60226126D1 (de)	2008-05-29	Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
SE0400522D0 (sv)	2004-03-01	A medical solution, a method for producing said medical solution and use thereof
EA200500235A1 (ru)	2005-08-25	Новые производные пиперазинона для лечения нарушений, связанных с 5-ht-рецептором